Protagonist Therapeutics, Inc
rusfertide
polycythemia vera
Resolved
35days ago
FDA decision · Aug 31, 2026
What's at stake
The FDA's approval decision on rusfertide for polycythemia vera is due Aug 31, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 3mo ago
“A U.S. regulatory decision is anticipated in 2026 with potential approval and launch this year”